Akero Therapeutics Inc (NASDAQ:AKRO) has coverage initiated with a Overweight rating

Analyst Ratings For Akero Therapeutics Inc (NASDAQ:AKRO)

Story continues below

Today, JPMorgan Chase & Co. initiated coverage on Akero Therapeutics Inc (NASDAQ:AKRO) with a Overweight.

There are 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Akero Therapeutics Inc (NASDAQ:AKRO) is Buy with a consensus target price of N/A per share, a potential N/A.

Some recent analyst ratings include

  • 7/15/2019-Akero Therapeutics Inc (NASDAQ:AKRO) has coverage initiated with a Overweight rating

    Recent Trading Activity for Akero Therapeutics Inc (NASDAQ:AKRO)
    Shares of Akero Therapeutics Inc closed the previous trading session at 19.88 up +1.51 8.22% with 18.59 shares trading hands.

    An ad to help with our costs